Synthesis and biological evaluation of novel pyrrolidine-2,5-dione derivatives as potential antidepressant agents. Part 1

European Journal of Medicinal Chemistry

Volumn 63, Issue , 2013, Pages 484-500

  Wróbel, Martyna Z ^a   Chodkowski, Andrzej ^a   Herold, Franciszek ^a   Gomółka, Anna ^a   Kleps, Jerzy ^a   Mazurek, Aleksander P ^a,b   Pluciński, Franciszek ^b   Mazurek, Andrzej ^b   Nowak, Gabriel ^c,d   Siwek, Agata ^d   Stachowicz, Katarzyna ^c   Sławińska, Anna ^c   Wolak, Małgorzata ^d   Szewczyk, Bernadeta ^c   Satała, Grzegorz ^c   Bojarski, Andrzej J ^c   Turło, Jadwiga ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b NATIONAL MEDICINES INSTITUTE   (Poland)

^c INSTITUTE OF PHARMACOLOGY   (Poland)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

5 HT1A receptor ligands; 5 HT1A SERT dual activity; Antidepressants; D2 5 HT2A receptor ligands; Pyrrolidine 2,5 dione; Serotonin reuptake inhibitors

Indexed keywords

1 (2 BROMOETHYL) 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 1 (3 BROMOPROPYL) 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 1 (4 BROMOBUTYL) 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 1 [2 [4 (1H INDOL 3 YL) 3,6 DIHYDRO 2H PYRIDIN 1 YL]ETHYL] 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 1 [2 [4 (1H INDOL 3 YL)PIPERIDIN 1 YL]ETHYL] 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 1 [2 [4 (5 BROMO 1H INDOL 3 YL) 3,6 DIHYDRO 2H PYRIDIN 1 YL]ETHYL] 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 1 [2 [4 (5 CHLORO 1H INDOL 3 YL) 3,6 DIHYDRO 2H PYRIDIN 1 YL]ETHYL] 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 1 [2 [4 (5 FLUORO 1H INDOL 3 YL) 3,6 DIHYDRO 2H PYRIDIN 1 YL]ETHYL] 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 1 [2 [4 (5 FLUORO 1H INDOL 3 YL)PIPERIDIN 1 YL]ETHYL] 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 1 [2 [4 (5 METHOXY 1H INDOL 3 YL) 3,6 DIHYDRO 2H PYRIDIN 1 YL]ETHYL] 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 1 [2 [4 (5 METHOXY 1H INDOL 3 YL)PIPERIDIN 1 YL]ETHYL] 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 1 [3 [4 (1H INDOL 3 YL) 3,6 DIHYDRO 2H PYRIDIN 1 YL]PROPYL] 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 1 [3 [4 (1H INDOL 3 YL)PIPERIDIN 1 YL]PROPYL] 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 1 [3 [4 (5 BROMO 1H INDOL 3 YL) 3,6 DIHYDRO 2H PYRIDIN 1 YL]PROPYL] 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 1 [3 [4 (5 CHLORO 1H INDOL 3 YL) 3,6 DIHYDRO 2H PYRIDIN 1 YL]PROPYL] 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 1 [3 [4 (5 FLUORO 1H INDOL 3 YL) 3,6 DIHYDRO 2H PYRIDIN 1 YL]PROPYL] 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 1 [3 [4 (5 FLUORO 1H INDOL 3 YL)PIPERIDIN 1 YL]PROPYL] 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 1 [3 [4 (5 METHOXY 1H INDOL 3 YL) 3,6 DIHYDRO 2H PYRIDIN 1 YL]PROPYL] 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 1 [3 [4 (5 METHOXY 1H INDOL 3 YL)PIPERIDIN 1 YL]PROPYL] 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 1 [4 [4 (1H INDOL 3 YL) 3,6 DIHYDRO 2H PYRIDIN 1 YL]BUTYL] 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 1 [4 [4 (1H INDOL 3 YL)PIPERIDIN 1 YL]BUTYL] 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 1 [4 [4 (5 BROMO 1H INDOL 3 YL) 3,6 DIHYDRO 2H PYRIDIN 1 YL]BUTYL] 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 1 [4 [4 (5 CHLORO 1H INDOL 3 YL) 3,6 DIHYDRO 2H PYRIDIN 1 YL]BUTYL] 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 1 [4 [4 (5 FLUORO 1H INDOL 3 YL) 3,6 DIHYDRO 2H PYRIDIN 1 YL]BUTYL] 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 1 [4 [4 (5 METHOXY 1H INDOL 3 YL) 3,6 DIHYDRO 2H PYRIDIN 1 YL]BUTYL] 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 1 [4 [4 (5 METHOXY 1H INDOL 3 YL)PIPERIDIN 1 YL]BUTYL] 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; 3 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; ANTIDEPRESSANT AGENT; NALUZOTAN; OSEMOZOTAN; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILAZODONE;

ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BODY TEMPERATURE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; EVALUATION; FORCED SWIMMING TEST; HUMAN; HUMAN CELL; HYDROGEN BOND; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RECEPTOR AFFINITY; SIMULATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; BINDING, COMPETITIVE; BODY TEMPERATURE; BRAIN; HEK293 CELLS; HUMANS; INDOLES; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MOTOR ACTIVITY; PROTEIN STRUCTURE, TERTIARY; PYRROLIDINES; PYRROLIDINONES; RADIOLIGAND ASSAY; RATS; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN AGENTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SWIMMING;

EID: 84875128862     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.02.033     Document Type: Article

References (75)

1. R. Kessler, W. Chiu, O. Demler, and E.E. Walters Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication Arch. Gen. Psychiatry 62 June 2005 617 709
2. F. Artigas, A. Adell, and P. Celada Pindolol augmentation of antidepressant response Curr. Drug Targets 7 2 2006 139 147
3. A. Newman-Tancredi Biased agonism at serotonin 5-HT1A receptors: preferential postsynaptic activity for improved therapy of CNS disorders Neuropsychiatry 1 2 2011 149 164
4. K. Rickels, and M. Athanasiou Vilazodone, a novel, dual-acting antidepressant: current status, future promise and potential for individualized treatment of depression Pers. Med. 6 2 2009 217 224
5. T. Sharp, and P.J. Cowen 5-HT and depression: is the glass half-full? Curr. Opin. Pharmacol. 11 1 2011 45 51
6. P. Blier The pharmacology of putative early-onset antidepressant strategies Eur. Neuropsychopharmacol. 13 2 2003 57 66
7. A. Adell, E. Castro, P. Celada, A. Bortolozzi, A. Pazos, and F. Artigas Strategies for producing faster acting antidepressants Drug Discov. Today 10 8 2005 578 585
8. G.V. Carr, and I. Lucki The role of serotonin receptor subtypes in treating depression: a review of animal studies Psychopharmacology 213 2-3 2011 265 287
9. E. Lacivita, M. Leopoldo, and F. Berardi 5-HT1A receptor, an old target for new therapeutic agents Curr. Top. Med. Chem. 8 2008 1024 1034
10. D.E. Nichols, and C.D. Nichols Serotonin receptors Chem. Rev. 108 5 2008 1614 1641
11. Y. Ohno Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease CNS Neurosci. Ther. 17 1 2011 58 65
12. M. Pytliak, V. Vargová, V. Mechírová, and M. Felšöci Serotonin receptors-from molecular biology to clinical applications Physiol. Res. 60 1 2011 15 25
13. F. Artigas 5-HT and antidepressants: new views from microdialysis studies Trends Pharmacol. Sci. 14 1993 34
14. S.M. Bromidge, R. Arban, B. Bertani, M. Borriello, A.-M. Capelli, R. Di-Fabio, S. Faedo, M. Gianotti, L.J. Gordon, E. Granci, A. Pasquarello, S.K. Spada, A. Worby, L. Zonzini, and V. Zucchelli 5-{2-[4-(2-Methyl-5-quinolinyl)-1- piperazinyl]ethyl}-2(1H)-quinolinones and 3,4-dihydro-2(1H)-quinolinones: dual-acting 5-HT1 receptor antagonists and serotonin reuptake inhibitors. Part 3 Bioorg. Med. Chem. Lett. 20 23 2010 7092 7096
15. Z. Weng, and J. Li Synthesis and antidepressant activity of optical isomers of 2-(4-benzylpiperazin-1-yl)-1-(5-chloro-6-methoxynaphthalen-2-yl) propan-1-ol (SIPI5056) Bioorg. Med. Chem. Lett. 20 3 2010 1256 1259
16. D. Zhou, G.P. Stack, J. Lo, A. Failli, D. Evrard, B.L. Harrison, N.T. Hatzenbuhler, M. Tran, S. Croce, S. Yi, J. Golembieski, G.A. Hornby, M. Lai, Q. Lin, L.E. Schechter, D.L. Smith, A.D. Shilling, C. Huselton, P. Mitchell, C.E. Beyer, and T.H. Andree Synthesis, potency, and in vivo evaluation of 2-piperazin-1-ylquinoline analogues as dual serotonin reuptake inhibitors and serotonin 5-HT1A receptor antagonists J. Med. Chem. 52 15 2009 4955 4959
17. J. Martinez-Esparza, and A. Oficialdegui New 1-aryl-3-(4-arylpiperazin-1- yl) propane derivatives, with dual action at 5-HT1A serotonin receptors and serotonin transporter, as a new class of antidepressants J. Med. Chem. 44 2001 418 428
18. A. Li, X. Zhang, X. Zhou, and D. Liu New 3-(4-arylpiperazin-1-yl)-1- (benzo[b]thiophen-3-yl)-2-methylpropanol derivatives: synthesis and evaluation for dual 5-HT1A/SSRI activities Chin. Chem. Lett. 19 4 2008 412 414
19. N. Hatzenbuhler, R. Baudy, and D. Evrard Advances toward new antidepressants with dual serotonin transporter and 5-HT1A receptor affinity within a class of 3-aminochroman derivatives. Part 2 J. Med. Chem. 51 2008 6980 7004
20. P.J. Lovell, F.E. Blaney, C.J. Goodacre, C.M. Scott, P.W. Smith, K.R. Starr, K.M. Thewlis, A.K. Vong, S.E. Ward, and J.M. Watson 3,4-Dihydro-2H- benzoxazinones as dual-acting 5-HT1A receptor antagonists and serotonin reuptake inhibitors Bioorg. Med. Chem. Lett. 17 4 2007 1033 1036
21. K. Takeuchi, T.J. Kohn, N.A. Honigschmidt, V.P. Rocco, P.G. Spinazze, D.J. Koch, S.T. Atkinson, L.W. Hertel, D.L. Nelson, D.B. Wainscott, L.J. Ahmad, J. Shaw, P.G. Threlkeld, and D.T. Wong Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 2 Bioorg. Med. Chem. Lett. 13 14 2003 2393 2397
22. V.P. Rocco, P.G. Spinazze, T.J. Kohn, N.A. Honigschmidt, D.L. Nelson, D.B. Wainscott, L.J. Ahmad, J. Shaw, P.G. Threlkeld, D.T. Wong, and K. Takeuchi Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan- 2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 4 Bioorg. Med. Chem. Lett. 14 10 2004 2653 2656
23. R.M. Tordera, A. Monge, J. Del Rio, and B. Lasheras Antidepressant-like activity of VN2222, a serotonin reuptake inhibitor with high affinity at 5-HT 1A receptors Eur. J. Pharmacol. 442 2002 63 71
24. M.E. Page, J.F. Cryan, A. Sullivan, A. Dalvi, B. Saucy, D.R. Manning, and I. Lucki Behavioral and neurochemical effects of 5-(4-[4-(5-cyano-3-indolyl)- butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist J. Pharmacol. Exp. Ther. 302 3 2002 1220 1227
25. L. Romero, P. Celada, R. Martín-Ruiz, L. Díaz-Mataix, M. Mourelle, J. Delgadillo, I. Hervás, and F. Artigas Modulation of serotonergic function in rat brain by VN2222, a serotonin reuptake inhibitor and 5-HT1A receptor agonist Neuropsychopharmacology 28 3 2003 445 456
26. D. Spinks, and G. Spinks Serotonin reuptake inhibition: an update on current research strategies Curr. Med. Chem. 9 8 2002 799 810
27. J.F. Cryan, R.J. Valentino, and I. Lucki Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test Neurosci. Biobehav. Rev. 29 4-5 2005 547 569
28. S. Hjorth, H. Bengtsson, and A. Kullberg Serotonin autoreceptor function and antidepressant drug action J. Psychopharmacol. 14 2 2000 177 185
29. P. Blier, and N. Ward Is there a role for 5-HT1A agonists in the treatment of depression? Biol. Psychiatry 53 3 2003 193 203
30. P. Blier, and C. de Montigny Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain Synapse 1 5 1987 470 480
31. R.H. Howland Vilazodone another novel atypical antidepressant drug J. Psychosoc. Nurs. 49 3 2011 19 22
32. J.E. Frampton Vilazodone: in major depressive disorder CNS Drugs 25 7 2011 615 627
33. F. Herold, A. Chodkowski, Ł. Izbicki, M. Król, J. Kleps, J. Turło, G. Nowak, K. Stachowicz, M. Dybała, and A. Siwek Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity, part 1 Eur. J. Med. Chem. 44 4 2009 1710 1717
34. F. Herold, Ł. Izbicki, A. Chodkowski, M. Dawidowski, M. Król, J. Kleps, J. Turło, I. Wolska, G. Nowak, K. Stachowicz, M. Dybała, A. Siwek, M. Nowak, E. Pieniazek, M. Jarończyk, I. Sylte, and A.P. Mazurek Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity: part 2 Eur. J. Med. Chem. 44 11 2009 4702 4715
35. F. Herold, A. Chodkowski, Ł. Izbicki, J. Turło, M. Dawidowski, J. Kleps, G. Nowak, K. Stachowicz, M. Dybała, A. Siwek, A.P. Mazurek, A. Mazurek, and F. Plucinski Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT(1A) activity. part 3 Eur. J. Med. Chem. 46 1 2011 142 149
36. J. Malleron, C. Gueremy, and C. Mignani New indole derivatives as potent and selective serotonin uptake inhibitors J. Med. Chem. 36 1993 1194 1202
37. R. van Hes, P. Smid, C.G. Kruse, M.T.M. Tulp, Tetrahydropyridin-4-yl Indoles with a Combination of Affinity for Dopamine-D2 Receptors and Serotonin Reuptake Sites, U.S. Patent WO/2006/061373, 2006.
38. A. Bojarski, M. Mokrosz, B. Duszyńska, and A. Kozioł New imide 5-HT1a receptor ligands-modification of terminal fragment geometry Molecules 9 2004 170 177
39. A.M. Venkatesan, O. Dos Santos, J. Ellingboe, D.A. Evrard, B.L. Harrison, D.L. Smith, R. Scerni, G.A. Hornby, L.E. Schechter, and T.H. Andree Novel benzofuran derivatives with dual 5-HT1A receptor and serotonin transporter affinity Bioorg. Med. Chem. Lett. 20 3 2010 824 827
40. M.L. López-Rodríguez, M.J. Morcillo, T.K. Rovat, E. Fernández, B. Vicente, A.M. Sanz, M. Hernández, and L. Orensanz Synthesis and structure-activity relationships of a new model of arylpiperazines. 4. 1-[ω-(4-Arylpiperazin-1-yl)alkyl]-3- (diphenylmethylene)-study of the steric requirements of the terminal amide fragment on 5-HT1A affinity/selectivity J. Med. Chem. 42 1999 36 49
41. M. Pawłowski, G. Chłoń, J. Obniska, A. Zejc, S. Charakchieva-Minol, and M.J. Mokrosz Synthesis, 5-HT1A and 5-HT2A receptor affinity of new1-phenylpiperazinylpropyl derivatives of purine-2,6- and pyrrolidine-2,5-diones Il Farmaco 55 2000 461 468
42. M.H. Paluchowska, M.J. Mokrosz, A. Bojarski, A. Wesołowska, J. Borycz, S. Charakchieva-Minol, and E. Chojnacka-Wójcik On the bioactive conformation of NAN-190(1) and MP3022 (2), 5-HT(1A) receptor antagonists J. Med. Chem. 42 24 1999 4952 4960
43. A.J. Bojarski Pharmacophore models for metabotropic 5-HT receptor ligands Curr. Top. Med. Chem. 6 18 2006 2005 2026
44. M.L. López-Rodríguez, M.L. Rosado, B. Benhamú, M.J. Morcillo, A.M. Sanz, L. Orensanz, M.E. Beneitez, J.A. Fuentes, and J. Manzanares Synthesis and structure-activity relationships of a new model of arylpiperazines. 1. 2-[[4-(o-Methoxyphenyl)piperazin-1-yl]methyl]-1,3- dioxoperhydroimidazo[1,5-a]pyridine: a selective 5-HT1A receptor agonist J. Med. Chem. 2623 96 1996 4439 4450
45. J.A. Deskus, J.R. Epperson, C.P. Sloan, J.A. Cipollina, P. Dextraze, J. Qian-Cutrone, Q. Gao, B. Ma, B.R. Beno, G.K. Mattson, T.F. Molski, R.G. Krause, M.T. Taber, N.J. Lodge, and R.J. Mattson Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors Bioorg. Med. Chem. Lett. 17 11 2007 3099 3104
46. W.D. Schmitz, D.J. Denhart, A.B. Brenner, J.L. Ditta, R.J. Mattson, G.K. Mattson, T.F. Molski, and J.E. Macor Homotryptamines as potent and selective serotonin reuptake inhibitors (SSRIs) Bioorg. Med. Chem. Lett. 15 6 2005 1619 1621
47. J. Bergman, E. Desabre, and E. Koch Synthesis of indolo[3,2-a]pyrrolo[3, 4-c]carbazole in one step from indole and maleimide Tetrahedron 55 1999 2363 2370
48. H. Hénon, S. Messaoudi, B. Hugon, F. Anizon, B. Pfeiffer, and M. Prudhomme Synthesis of granulatimide bis-imide analogues Tetrahedron 61 23 2005 5599 5614
49. J.E. Macor, D.H. Blank, K. Ryan, and R.J. Post A direct synthesis of 3-(pyrrolidin-3-yl)indoles for use as conformationally restricted analogs of tryptamines Synthesis 1997 4 1997 443 449
50. J.E. Macor, C.A. Burkhart, J.H. Heym, J.L. Ives, L.A. Lebel, M.E. Newman, J.A. Nielsen, K. Ryan, D.W. Schulz, L.K. Torgersen, and B.K. Koe 3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one: a apotent and selective serotonin (5-HT1B) agonist and rotationally restricted phenolic analogue of 5-methoxy-3-(1,2,5,6-terahydropyrid-4-yl)indole J. Med. Chem. 33 11 1990 2087 2093
51. J. Guillaume, C. Dumont, J. Laurent, and L. Nedelec Synthesis of 3-(1,2,3,6-tetrahydro pyridin-4-yl) 1H-indoles and study of their serotoninergic and anti-dopaminergic properties Eur. J. Med. Chem. 22 1 1987 33 43
52. P. Gharagozloo, and M. Miyauchi 3-(Tetrahydropyridinyl) indoles Tetrahedron 52 30 1996 10185 10192
53. S. Fonquerna, M. Miralpeix, L. Pagès, C. Puig, A. Cardús, F. Antón, A. Cárdenas, D. Vilella, M. Aparici, E. Calaf, J. Prieto, J. Gras, J.M. Huerta, G. Warrellow, J. Beleta, and H. Ryder Synthesis and structure-activity relationships of novel histamine H1 antagonists: indolylpiperidinyl benzoic acid derivatives J. Med. Chem. 47 25 2004 6326 6337
54. A. Agarwal, P.P. Pearson, E.W. Taylor, H.B. Li, T. Dahlgren, M. Herslof, Y. Yang, G. Lambert, D.L. Nelson, J.W. Regan, and A.R. Martin Three-dimensional quantitative structure-activity relationships of 5-HT receptor binding data for tetrahydropyridinylindole derivatives: a comparison of the Hansch and CoMFA methods J. Med. Chem. 36 1993 4006 4014
55. R.E. Mewshaw, K.L. Meagher, P. Zhou, D. Zhou, X. Shi, R. Scerni, D. Smith, L.E. Schechter, and T.H. Andree Studies toward the discovery of the next generation of antidepressants. Part 2: incorporating a 5-HT(1A) antagonist component into a class of serotonin reuptake inhibitors Bioorg. Med. Chem. Lett. 12 3 2002 307 310
56. M.L. López-Rodríguez, M.L. Rosado, B. Benhamu, M.J. Morcillo, E. Fernandez, and K.-J. Schaper Synthesis and structure-activity relationships of a new model of arylpiperazines. 2.1 Three-dimensional quantitative structure-activity relationships of hydantoin-phenylpiperazine derivatives with affinity for 5-HT1A and α1 receptors. A comparison of CoMFA models J. Med. Chem. 40 1997 1648 1656
57. G. Husbands, G.P. Stack, R.E. Mewshaw, I.A. Cliffe, Antidepressant Azaheterocyclylmethyl Derivatives of 2,3-Dihydro-1,4-Benzodioxan, WO Patent WO/2002/085,896, 2002.
58. G. Di Giovanni, E. Esposito, and V. Di Matteo Role of serotonin in central dopamine dysfunction CNS Neurosci. Ther. 16 3 2010 179 194
59. A. Etievant, C. Bétry, and N. Haddjeri Partial dopamine D2/serotonin 5-HT1A receptor agonists as new therapeutic agents Open Neuropsychopharmacol. J. 3 2010 1 12
60. M. Sakaue, P. Somboonthum, B. Nishihara, Y. Koyama, H. Hashimoto, A. Baba, and T. Matsuda Postsynaptic 5-hydroxytryptamine(1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex Br. J. Pharmacol. 129 5 2000 1028 1034
61. R. van Hes, P. Smid, C.N.J. Stroomer, K. Tipker, M.T.M. Tulp, J.A.M. van der Heyden, A.C. McCreary, M.B. Hesselink, and G.C. Kruse SLV310, a novel, potential antipsychotic, combining potent dopamine D 2 receptor antagonism with serotonin reuptake inhibition Bioorg. Med. Chem. Lett. 13 2003 405 408
62. K.N. Fountoulakis, J.R. Kelsoe, and H. Akiskal Receptor targets for antidepressant therapy in bipolar disorder: an overview J. Affect. Disord. 138 3 2012 222 238
63. M.J. Millan Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application Pharmacol. Ther. 110 2 2006 135 370
64. G. Goodwin, and R.D. Souza The pharmacology of the hypothermic response in mice to 8-hydroxy-2-(DI-n-propylamino) tetralin (8-OH-DPAT): a model of presynaptic 5-HT1 function Neuropharmacology 24 1985 1187 1194
65. K. Martin, and D. Heal 8-OH-DPAT-induced hypothermia in rodents: a specific model of 5-HT1A autoreceptor function J.R. Fozard, P.R. Saxena, Serotonin: Molecular Biology, Receptors and Functional Effects 1991 Birkhauser Verlag Basel 483 490
66. E.A. Forster, I. Cliffe, D. Bill, G. Dover, D. Jones, Y. Reilly, and A. Fletcher A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635 E. J. Pharmacol. 281 1 1995 81 88
67. Schrödinger Suite 2008, Glide Version 5.0 2006 Schrödinger, LLC New York, NY
68. A.A. Strzelczyk, M. Jarończyk, Z. Chilmonczyk, A.P. Mazurek, E. Chojnacka-Wójcik, and I. Sylte Intrinsic activity and comparative molecular dynamics of buspirone analogues at the 5-HT(1A) receptors Biochem. Pharmacol. 67 12 2004 2219 2230
69. Q. Wang, R.H. Mach, R.R. Luedtke, and D.E. Reichert Subtype selectivity of dopamine receptor ligands: insights from structure and ligand-based methods J. Chem. Inf. Model. 50 11 2010 1970 1985
70. V. Cherezov, D.M. Rosenbaum, M.A. Hanson, S.G.F. Rasmussen, F.S. Thian, T.S. Kobilka, H.-J. Choi, P. Kuhn, W.I. Weis, B.K. Kobilka, and R.C. Stevens High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor Science 318 5854 2007 1258 1265
71. P. Zajdel, K. Marciniec, A. Maślankiewicz, G. Satała, B. Duszyńska, A.J. Bojarski, A. Partyka, M. Jastrzȩbska- Wiȩsek, D. Wróbel, A. Wesołowska, and M. Pawłowski Quinoline- and isoquinoline-sulfonamide derivatives of LCAP as potent CNS multi-receptor-5-HT1A/5-HT2A/5-HT7 and D2/D3/D4-agents: the synthesis and pharmacological evaluation Bioorg. Med. Chem. 20 2012 1545 1556
72. i) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 22 23 1973 3099 3108
73. M.H. Paluchowska, R. Bugno, B. Duszyńska, E. Tatarczyńska, A. Nikiforuk, T. Lenda, and E. Chojnacka-Wójcik The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m- trifluoromethylphenyl)piperazines Bioorg. Med. Chem. 15 22 2007 7116 7125
74. A.J. Bojarski, M.T. Cegła, S. Charakchieva-Minol, M.J. Mokrosz, M. Maćkowiak, S. Misztal, and J.L. Mokrosz Structure-activity relationship studies of CNS agents. Part 9: 5-HT1A and 5-HT2 receptor affinity of some 2- and 3-substituted 1,2,3,4-tetrahydro-beta-carbolines Pharmazie 48 4 1993 289 294
75. Discovery StudioClient V2.5.5.9350, Accelrys Software Inc.